About this trial
The goal of this clinical trial is to evaluate the effect of early propranolol administration on the occurrence of post-traumatic stress disorder (PTSD) symptoms at five weeks in adult female victims of sexual violence.
The investigators hypothesize that propranolol administration may reduce the traumatic emotional experience associated with the memory by positively modulating neurovegetative symptoms during the memory reconsolidation phase, thereby decreasing the risk of developing post-traumatic stress disorder (PTSD). This specific context of sexual violence appears particularly suitable, given the timeline of events, to evaluate the pharmacological efficacy of propranolol on memory reconsolidation and the prevention of post-traumatic symptom development.
Participants will :
* take Propranolol, 120mg per day divided into 3 daily doses of 40mg or a placebo for 10 days, followed by a tapering phase consisting of two daily doses of 40 mg for 7 days, and then a single daily dose of 40 mg for an additional 7 days. * Complete questionnaires * Complete a patient follow-up diary documenting information related to the occurrence of adverse events.
Eligibility criteria
Qualifiers
female, cisgender
>= 18 years
The patient agrees to comply with the contraception requirements detailed in the protocol.
SBP > 10 cmHg
Disqualifiers
Protected adult (guardianship, curatorship, judicial protection)
Repeated or chronic sexual violence
Impaired consciousness or alertness, amnesia regarding events
Known hypersensitivity to propranolol or treated asthma, even if only occasional
Trial design
Treatments tested in this trial
- Propranolol, 120mg
- Placebo
Treatment groups
Locations
Sponsors and collaborators
University Hospital, Tours
Lead sponsor
Fondation Matmut Paul Bennetot
Collaborator